Intracavernous injection therapy for male erectile dysfunction

Area of Science:

• Urology
• Andrology
• Pharmacology

Background:

• Intracavernosal injection therapy is a common treatment for erectile dysfunction.
• Success rates vary, and patient adherence can be challenging due to dropout.
• Optimizing treatment regimens and patient education are crucial for long-term success.

Purpose of the Study:

• To evaluate the efficacy and outcomes of intracavernosal injection therapy for erectile dysfunction.
• To identify the most effective current therapeutic regimens.
• To highlight the importance of patient education and satisfaction in treatment programs.

Main Methods:

• Review of existing data on intracavernosal injection therapy outcomes.
• Analysis of patient entry into long-term therapy and dropout rates.
• Assessment of the effectiveness and side effect profile of combination therapies.

Main Results:

• Intracavernosal injections achieve erections in 60% to 70% of patients.
• A combination of papaverine-phentolamine and prostaglandin E1 shows high efficacy.
• This combination regimen is associated with a low incidence of priapism and fibrous nodule formation.
• Patient education is vital for program success, with high patient satisfaction rates reported.

Conclusions:

• Intracavernosal injection therapy remains a highly effective treatment option for erectile dysfunction.
• The combination of papaverine-phentolamine and prostaglandin E1 is a preferred regimen due to efficacy and safety.
• Comprehensive patient education and support are essential for maximizing treatment success and patient satisfaction.